Bengaluru MP Requests Duty Exemption for Cancer Treatment Equipment

Bengaluru Rural Member of Parliament C.N. Manjunath has formally requested the Government of India to exempt customs duties on imported immunotherapy drugs and radiotherapy equipment. These items are increasingly vital in the fight against cancer, which has become a significant public health issue in India. Dr. Manjunath made this appeal during a meeting with Finance Minister Nirmala Seetharaman on March 13, 2024, in Delhi.

Dr. Manjunath emphasized the growing importance of these treatments, stating, “They are essential for treating various forms of cancer, often in combination with chemotherapy.” The costs for immunotherapy can be exorbitant, ranging from ₹20 lakh to ₹50 lakh per patient per treatment cycle. He highlighted that cancer, once seen as a rare disease in India, is now a widespread concern, largely due to lifestyle changes and food adulteration.

While the Indian government currently exempts customs duties on many chemotherapy drugs, immunotherapy drugs and radiotherapy equipment do not receive the same consideration. This lack of exemption poses a barrier for many cancer patients, particularly those from economically disadvantaged backgrounds. “A large number of cancer patients are unable to access this potentially life-saving therapy,” he noted.

In his meeting, Dr. Manjunath urged that customs duty exemptions on these critical items would significantly lower treatment costs, making cancer care more accessible to those in need. “This will help in making cancer treatment affordable, benefiting a large section of people belonging to the economically weaker section,” he added.

Dr. Manjunath reported that the Finance Minister responded positively to his request, indicating a willingness to consider the implications of this exemption. The outcome of this initiative could have profound implications for cancer care in India, potentially enabling more patients to receive necessary treatments without the burden of prohibitive costs.

As cancer rates continue to rise, the need for comprehensive policy changes and support for affordable treatment options remains urgent.